ValiRx plc (LSE:VAL) — Stock Price
ValiRx plc (LSE:VAL) is currently trading at £0.16 GBP, up 0.00% today. Over the past 52 weeks, shares have ranged between £0.15 and £0.75. This page tracks ValiRx plc's live share price on the LSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see ValiRx plc market cap and net worth.
ValiRx plc (VAL) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ValiRx plc's daily closing share price and trading volume on the LSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
ValiRx plc Income Statement — Revenue, Profit & Earnings by Year
ValiRx plc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | £49.77K | £9.60K | £0.00 | £0.00 | £0.00 |
| Cost of Revenue | £0.00 | £255.64K | £224.27K | £228.79K | £229.50K |
| Gross Profit | £-217.22K | £-246.04K | £-224.27K | £-228.79K | £-229.50K |
| Research & Development | £245.16K | £383.36K | £551.23K | £303.79K | £230.12K |
| SG&A | £1.98 Million | £1.89 Million | £1.50 Million | £1.22 Million | £1.43 Million |
| Total Operating Expenses | £2.19 Million | £2.05 Million | £2.59 Million | £1.68 Million | £1.65 Million |
| Operating Income | £-2.14 Million | £-2.30 Million | £-2.59 Million | £-1.68 Million | £-1.65 Million |
| EBITDA | £-1.86 Million | £-2.04 Million | £-2.37 Million | £-1.45 Million | £-1.31 Million |
| EBIT | £-2.13 Million | £-2.30 Million | £-2.59 Million | £-1.68 Million | £-1.54 Million |
| Interest Expense | £1.28K | £4.42K | £5.46K | £2.77K | £14.88K |
| Income Before Tax | £-2.13 Million | £-2.30 Million | £-2.60 Million | £-1.68 Million | £-1.54 Million |
| Income Tax Expense | £-127.70K | £-175.17K | £-192.67K | £-133.41K | £-75.18K |
| Net Income | £-1.92 Million | £-2.04 Million | £-2.41 Million | £-1.55 Million | £-1.47 Million |
ValiRx plc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ValiRx plc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | £4.26 Million | £3.13 Million | £3.98 Million | £3.52 Million | £4.94 Million |
| Total Current Assets | £1.90 Million | £566.48K | £1.46 Million | £800.01K | £1.98 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | £102.11K | £99.05K | £326.49K | £206.34K | £105.53K |
| Inventory | £69.00K | £69.00K | £0.00 | — | — |
| Property, Plant & Equipment | — | — | £5.56K | £13.28K | £21.00K |
| Goodwill | £1.60 Million | £1.60 Million | £1.60 Million | £1.60 Million | £1.60 Million |
| Total Liabilities | £346.41K | £226.51K | £149.65K | £109.56K | £182.40K |
| Total Current Liabilities | £345.02K | £214.65K | £127.58K | £68.22K | £124.48K |
| Long-term Debt | £1.39K | £11.86K | £22.07K | £35.65K | £44.49K |
| Net Debt | £-1.54 Million | £-152.61K | £-1.10 Million | £-534.95K | £-1.78 Million |
| Total Stockholder Equity | £4.32 Million | £3.22 Million | £4.05 Million | £3.60 Million | £4.91 Million |
| Retained Earnings | £-38.49 Million | £-36.68 Million | £-34.64 Million | £-32.29 Million | £-30.92 Million |
ValiRx plc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ValiRx plc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | £-1.58 Million | £-1.77 Million | £-1.71 Million | £-1.26 Million | £-1.91 Million |
| Capital Expenditures | £38.16K | £306.18K | £0.00 | £0.00 | £93.29K |
| Free Cash Flow | £-1.62 Million | £-2.08 Million | £-1.71 Million | £-1.26 Million | £-2.00 Million |
| Investing Cash Flow | £-38.16K | £-306.18K | — | — | £-91.29K |
| Financing Cash Flow | £3.00 Million | £1.12 Million | £2.26 Million | £7.34K | £3.85 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | £0.00 | £36.94K | £539.79K | £184.61K | £0.00 |
| Depreciation | £267.00K | £254.20K | £211.93K | £228.79K | £229.50K |
| Change in Cash | £1.38 Million | £-962.79K | £543.80K | £-1.25 Million | £1.85 Million |
ValiRx plc Earnings History — EPS Actual vs. Analyst Estimates
Track ValiRx plc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 25, 2025 | — | — | — |
| May 13, 2025 | — | — | — |
| Jan 03, 2025 | — | — | — |